Oncolytic H-1 Parvovirus Shows Safety and Signs of Immunogenic Activity in a First Phase I/IIa Glioblastoma Trial

Oncolytic virotherapy may be a means of improving the dismal prognosis of malignant brain tumors. The rat H-1 parvovirus (H-1PV) suppresses tumors in preclinical glioma models, through both direct oncolysis and stimulation of anticancer immune responses. This was the basis of ParvOryx01, the first p...

Descripción completa

Detalles Bibliográficos
Autores principales: Geletneky, Karsten, Hajda, Jacek, Angelova, Assia L., Leuchs, Barbara, Capper, David, Bartsch, Andreas J., Neumann, Jan-Oliver, Schöning, Tilman, Hüsing, Johannes, Beelte, Birgit, Kiprianova, Irina, Roscher, Mandy, Bhat, Rauf, von Deimling, Andreas, Brück, Wolfgang, Just, Alexandra, Frehtman, Veronika, Löbhard, Stephanie, Terletskaia-Ladwig, Elena, Fry, Jeremy, Jochims, Karin, Daniel, Volker, Krebs, Ottheinz, Dahm, Michael, Huber, Bernard, Unterberg, Andreas, Rommelaere, Jean
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society of Gene & Cell Therapy 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768665/
https://www.ncbi.nlm.nih.gov/pubmed/28967558
http://dx.doi.org/10.1016/j.ymthe.2017.08.016

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5768665/
https://www.ncbi.nlm.nih.gov/pubmed/28967558
http://dx.doi.org/10.1016/j.ymthe.2017.08.016

Ejemplares similares